Company drops effort to develop 'pink Viagra'
Citing insurmountable regulatory hurdles, the pharmaceutical company that's been working to develop a drug to boost women's libidos has abandoned that effort.
The German pharmaceutical company Boehringer Engelheim announced Friday afternoon that it was ceasing research on its one-a-day oral pill containing flibanserin, dubbed "pink Viagra" for its potential to help women with low sex drive boost their sexual desire. The company hadn't been able to convince the U.S. Food and Drug Administration that the drug was useful enough in combating "hypoactive sexual desire disorder" to justify its side effects, which were common among women testing the drug and included depression, fatigue and fainting.
The company says it didn't make the decision lightly, as it had already poured lots of resources into developing and testing the drug. They've decided to focus on other drugs that have better potential to make it to market.
Jennifer LaRue Huget
| October 8, 2010; 2:32 PM ET
Categories: FDA, Sex, Women's Health, drug safety
Save & Share: Previous: Diet drug Meridia pulled over heart attack, stroke issues
Next: Yoga: WWJD?
Posted by: georgettec28 | October 9, 2010 10:18 AM | Report abuse
Posted by: James10 | October 9, 2010 11:31 AM | Report abuse